July 11, 2017
BlackThorn Therapeutics Appoints Dr. Atul R. Mahableshwarkar Vice President of Clinical Development
South San Francisco, Calif. – July 11, 2017 – BlackThorn Therapeutics, a clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, today announced the appointment of Atul R. Mahableshwarkar, MBBS, to the position of vice president of clinical development. Dr. Mahableshwarkar has extensive experience as a practicing clinician providing care to patients with psychiatric disorders and 15 years of experience in the pharmaceutical industry developing drugs for neurobehavioral disorders. His most recent efforts led to the U.S. Food and Drug Administration (FDA) approval of Trintellix® (vortioxetine), a serotonin modulator, for the treatment of major depressive disorder (MDD).
Dr. Mahableshwarkar is a highly accomplished neuropsychiatrist who brings deep CNS expertise and a rigorous clinical development background to our team,” said Annette Madrid, M.D., chief medical officer of BlackThorn Therapeutics. “He has been involved in the development of multiple CNS drugs, including leading the team that brought Trintellix to market. Dr. Mahableshwarkar will play a key role in leading and expanding on our clinical trial strategy, which is focused on early signal seeking, deep digital phenotyping of patients and assessment of treatment effect before advancing to late-stage clinical development.”
Dr. Mahableshwarkar has been responsible for the clinical development of drugs for MDD, anxiety disorder, bipolar disorder, schizophrenia and insomnia. He joined BlackThorn from Takeda, where he was senior medical director, clinical science, Global R&D. In that position, he was the team leader for vortioxetine in trials being conducted worldwide. Prior to Takeda, Dr. Mahableshwarkar served as director of GlaxoSmithKline’s Neurosciences Medical Development Center. Before joining GlaxoSmithKline, he was director of clinical development at Janssen Pharmaceuticals, Inc. Prior to his career in the pharmaceutical industry, he spent 13 years in academia. Most recently, Dr. Mahableshwarkar was leader, Primary Care Mental Health, and director, ECT Services, at the North Chicago VA Medical Center and associate professor of clinical psychiatry at The Chicago Medical School. Dr. Mahableshwarkar has an MBBS from the Armed Forces Medical College in India. He completed a residency in general adult psychiatry and a fellowship in neuropsychiatry at The Chicago Medical School.
About BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments. BlackThorn has a robust pipeline of first- and best-in-class treatments. The company approaches drug discovery and development by linking brain physiology to behavior. Through BlackThorn’s network of collaborations with leading academic investigators and technology alliances, the company is developing and deploying a set of technologies that will enable focused, rapid, resource-efficient translational studies for drug development. The company is headquartered in South San Francisco, Calif. For more information, please visit http://www.blackthornrx.com/.